Advertisement
Advertisement
U.S. Markets close in 1 hr 26 mins
Advertisement
Advertisement
Advertisement
Advertisement

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
14.72-0.37 (-2.45%)
As of 04:00PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.09
Open15.20
Bid14.22 x 1800
Ask15.35 x 800
Day's Range14.23 - 15.20
52 Week Range8.88 - 34.79
Volume381,479
Avg. Volume423,203
Market Cap547.918M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMay 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est39.50
  • GlobeNewswire

    Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

    – Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates and baseline data from ATH-1017’s ongoing Phase 2 and Phase 2/3 clinical trials at the 2021 CTAD conference – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neurona

  • GlobeNewswire

    Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

    – Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Hans Moebius, M.D., Ph.D., Chief Medical Officer at Athira, presented an overview and updates from two ongoing late-st

  • GlobeNewswire

    Athira Pharma to Present at Upcoming Investor Conferences

    -Stifel 2021 Virtual Healthcare Conference-- Jefferies 2021 London Healthcare Conference- BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences: Stifel’s 2021 Virtual Healthcare Conference Format: Fireside chatDate & Time:

Advertisement
Advertisement